RASSF2 and malignant colon neoplasm: Survival analysis reveals that the low RASSF2 mRNA expression (possibly due to hypermethylation of the RASSF2 promoter) predicts significant worse overall survival in 438 patients with colon cancer (p score: 0.038, expression of RASSF2 in colorectal cancer-The Human Protein Atlas, Figure S5).